http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 07:31:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html <p>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer, the company announced Oct. 15, 2026. Dr. David will oversee finance, accounting, capital markets and investor relations, and will serve as the company's principal financial officer.</p> <p>Dr. David joins Actinium from CorMedix Inc. (Nasdaq: CRMD), where he most recently served as Executive Vice President and Chief Business Officer. He joined CorMedix in 2020 as Executive Vice President and Chief Financial Officer. During his time there, CorMedix received U.S. Food and Drug Administration approval of DefenCath® in 2023, launched the product commercially in 2024, and acquired a commercial http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html Thu, 15 Oct 2026 07:31:14 -0400 ATNM CRMD OVID http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html <p>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer, the company announced Oct. 15, 2026. Dr. David will oversee finance, accounting, capital markets and investor relations, and will serve as the company's principal financial officer.</p> <p>Dr. David joins Actinium from CorMedix Inc. (Nasdaq: CRMD), where he most recently served as Executive Vice President and Chief Business Officer. He joined CorMedix in 2020 as Executive Vice President and Chief Financial Officer. During his time there, CorMedix received U.S. Food and Drug Administration approval of DefenCath® in 2023, launched the product commercially in 2024, and acquired a commercial http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html Thu, 15 Oct 2026 07:31:14 -0400 ATNM CRMD OVID http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html <p>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer, the company announced Oct. 15, 2026. Dr. David will oversee finance, accounting, capital markets and investor relations, and will serve as the company's principal financial officer.</p> <p>Dr. David joins Actinium from CorMedix Inc. (Nasdaq: CRMD), where he most recently served as Executive Vice President and Chief Business Officer. He joined CorMedix in 2020 as Executive Vice President and Chief Financial Officer. During his time there, CorMedix received U.S. Food and Drug Administration approval of DefenCath® in 2023, launched the product commercially in 2024, and acquired a commercial http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Matt+David+as+CFO/27189701.html Thu, 15 Oct 2026 07:31:14 -0400 ATNM CRMD OVID http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Oct. 15, 2026</chron></span> /PRNewswire/ -- <b><span value="AMEX:ATNM" idsrc="xmltag.org" >Actinium Pharmaceuticals, Inc.</span></b> (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of <person>Matt David</person>, M.D., as Chief Financial Officer. <person>Dr. David</person> will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.</p> http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals+Strengthens+Leadership+Team+with+Appointment+of+Matt+David%2C+M.D.+as+Chief+Financial+Officer/27189683.html Thu, 15 Oct 2026 07:30:00 -0400 ATNM CRMD OVID http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Outperform/27188678.html <p>Wolfe Research initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Outperform rating and a price target of $5.00.</p><p>For an analyst ratings summary and ratings history on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/rating_history.php?q=OVID">click here</a>. For more ratings news on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=OVID&amp;type=analyst">click here</a>.</p><p>Shares of Ovid Therapeutics Inc closed at $2.19 yesterday.</p> http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Outperform/27188678.html Thu, 15 Oct 2026 05:34:27 -0400 OVID http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Outperform/27188678.html <p>Wolfe Research initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Outperform rating and a price target of $5.00.</p><p>For an analyst ratings summary and ratings history on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/rating_history.php?q=OVID">click here</a>. For more ratings news on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=OVID&amp;type=analyst">click here</a>.</p><p>Shares of Ovid Therapeutics Inc closed at $2.19 yesterday.</p> http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Outperform/27188678.html Thu, 15 Oct 2026 05:34:27 -0400 OVID http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Overweight/27168860.html <p>Cantor Fitzgerald initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Overweight rating.</p><p>For an analyst ratings summary and ratings history on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/rating_history.php?q=OVID">click here</a>. For more ratings news on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=OVID&amp;type=analyst">click here</a>.</p><p>Shares of Ovid Therapeutics Inc closed at $2.34 yesterday.</p> http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Overweight/27168860.html Fri, 09 Oct 2026 06:13:55 -0400 OVID http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Buy/27148778.html <p>Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Buy rating and a price target of $7.00.</p> <p>For an analyst ratings summary and ratings history on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/rating_history.php?q=OVID">click here</a>. For more ratings news on Ovid Therapeutics Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=OVID&amp;type=analyst">click here</a>.</p> <p>Shares of Ovid Therapeutics Inc closed at $2.38 yesterday.</p> http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Ovid+Therapeutics+Inc+%28OVID%29+at+Buy/27148778.html Mon, 05 Oct 2026 16:07:17 -0400 OVID http://www.streetinsider.com/Analyst+PT+Change/Ovid+Therapeutics+Inc+%28OVID%29+PT+Raised+to+%245+at+H.C.+Wainwright/27050612.html (Updated - September 11, 2026 6:57 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $5.00 (from $4.00) while maintaining a Buy rating.</p><p>The analyst commented: "Ovid Therapeutics has received regulatory clearance across multiple regions and has initiated the dose-confirmatory study to evaluate seizure reduction efficacy, safety and tolerability of OV329 in people living with treatment-resistant focal onset seizures (FOS). This global study is designed with registrational-level rigor to potentially support multiple future seizure indications for OV329. The study is slated to be completed in 2H27. Ovid has also received regulatory clearances and http://www.streetinsider.com/Analyst+PT+Change/Ovid+Therapeutics+Inc+%28OVID%29+PT+Raised+to+%245+at+H.C.+Wainwright/27050612.html Fri, 11 Sep 2026 06:57:54 -0400 OVID http://www.streetinsider.com/Analyst+Comments/Ovid+Therapeutics+Inc+%28OVID%29+PT+Raised+to+%245+at+H.C.+Wainwright/27050612.html (Updated - September 11, 2026 6:57 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $5.00 (from $4.00) while maintaining a Buy rating.</p><p>The analyst commented: "Ovid Therapeutics has received regulatory clearance across multiple regions and has initiated the dose-confirmatory study to evaluate seizure reduction efficacy, safety and tolerability of OV329 in people living with treatment-resistant focal onset seizures (FOS). This global study is designed with registrational-level rigor to potentially support multiple future seizure indications for OV329. The study is slated to be completed in 2H27. Ovid has also received regulatory clearances and http://www.streetinsider.com/Analyst+Comments/Ovid+Therapeutics+Inc+%28OVID%29+PT+Raised+to+%245+at+H.C.+Wainwright/27050612.html Fri, 11 Sep 2026 06:57:54 -0400 OVID http://www.streetinsider.com/Press+Releases/Ovid%C2%A0Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27022090.html <p align="justify">NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:</p> <ul type="disc"><li style="margin-top:6pt;">Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET</li><li style="margin-top:6pt;">H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET</li></ul> <p>Webcasts of the presentations can be accessed through the Events &amp; Presentations section of the company’s website at <a href="https://www.globenewswire.com/Tracker?data=XK2D8pqWoHyrgAFzucgBzIgAJfuFtaYaYBMup37nqG6oxx0nRifmR-q5MrdtRcr_Lm085_U2ZiIR8CjU2Ew5n1K5uSvXFXn1rc2QxNZTWuL0F2I59nqcQ-kZElyD4E9auHpNT3ghMnSBaAihmU92ZMF2Fa7iRaRi7kzyrt7KV1ydDNTvdoyBOHkd8OXzyHFXvM5dFGcJfhypzn0GDjHz72rFLJ6wYplxolkj28L7JSHokpqMntBpW82ZtjgppUSDD8hFrZmWjg4vDg8fkiXGLpFS6UUp9aEyBsJauuCjPCMV0ffKZuI3UBWjZbRBV8JtrYcyDflmyrLrRj6LdukuMTAZgAaGzUmLb_M4masLYO07pXK-bGnvo7zNzM-kk7CGBVWWKBFuV8owJ1gmpAmUlPhkB8C94wyGKpdbz_AFSSgIPDskAOktcv_VDREjOcr1Noj3dc_7hYE9lKmpWJ2aZMXoyu9gB9jwiK8kK_6-ZsxIbGpS1AQNoKvsEklgp9zf" rel="nofollow" target="_blank">investors.ovidrx.com</a>. An archived replay http://www.streetinsider.com/Press+Releases/Ovid%C2%A0Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27022090.html Thu, 03 Sep 2026 08:00:00 -0400 OVID http://www.streetinsider.com/Globe+Newswire/Ovid%C2%A0Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27022090.html <p align="justify">NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:</p> <ul type="disc"><li style="margin-top:6pt;">Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET</li><li style="margin-top:6pt;">H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET</li></ul> <p>Webcasts of the presentations can be accessed through the Events &amp; Presentations section of the company’s website at <a href="https://www.globenewswire.com/Tracker?data=XK2D8pqWoHyrgAFzucgBzIgAJfuFtaYaYBMup37nqG6oxx0nRifmR-q5MrdtRcr_Lm085_U2ZiIR8CjU2Ew5n1K5uSvXFXn1rc2QxNZTWuL0F2I59nqcQ-kZElyD4E9auHpNT3ghMnSBaAihmU92ZMF2Fa7iRaRi7kzyrt7KV1ydDNTvdoyBOHkd8OXzyHFXvM5dFGcJfhypzn0GDjHz72rFLJ6wYplxolkj28L7JSHokpqMntBpW82ZtjgppUSDD8hFrZmWjg4vDg8fkiXGLpFS6UUp9aEyBsJauuCjPCMV0ffKZuI3UBWjZbRBV8JtrYcyDflmyrLrRj6LdukuMTAZgAaGzUmLb_M4masLYO07pXK-bGnvo7zNzM-kk7CGBVWWKBFuV8owJ1gmpAmUlPhkB8C94wyGKpdbz_AFSSgIPDskAOktcv_VDREjOcr1Noj3dc_7hYE9lKmpWJ2aZMXoyu9gB9jwiK8kK_6-ZsxIbGpS1AQNoKvsEklgp9zf" rel="nofollow" target="_blank">investors.ovidrx.com</a>. An archived replay http://www.streetinsider.com/Globe+Newswire/Ovid%C2%A0Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27022090.html Thu, 03 Sep 2026 08:00:00 -0400 OVID http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26968757.html si-local-file:///var/storage/secattach/20260824/26968757.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26968757.html Mon, 24 Aug 2026 16:48:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26968757.html si-local-file:///var/storage/secattach/20260824/26968757.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26968757.html Mon, 24 Aug 2026 16:48:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26933134.html si-local-file:///var/storage/secattach/20260814/26933134.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26933134.html Fri, 14 Aug 2026 18:28:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26933134.html si-local-file:///var/storage/secattach/20260814/26933134.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+Rona+Jeffrey+A/26933134.html Fri, 14 Aug 2026 18:28:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932618.html si-local-file:///var/storage/secattach/20260814/26932618.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932618.html Fri, 14 Aug 2026 17:07:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932618.html si-local-file:///var/storage/secattach/20260814/26932618.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932618.html Fri, 14 Aug 2026 17:07:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932169.html si-local-file:///var/storage/secattach/20260814/26932169.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932169.html Fri, 14 Aug 2026 16:49:00 -0400 O.25512853 OVID http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932169.html si-local-file:///var/storage/secattach/20260814/26932169.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Ovid+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932169.html Fri, 14 Aug 2026 16:49:00 -0400 O.25512853 OVID